Introducing a pneumococcal vaccine to an existing influenza immunization program: vaccination rates and predictors of noncompliance - 03/09/11
Abstract |
Purpose |
Influenza vaccination has been recommended for all elderly people in The Netherlands since 1996, with greater than 80% compliance. It is unknown, however, if the addition of another vaccine to this immunization program will affect compliance.
Subjects and methods |
General practitioners offered a pneumococcal vaccine together with the yearly influenza vaccination to 3365 patients aged 65 years and older. A questionnaire was then mailed to a stratified sample (n = 972) of these patients. Factors associated with noncompliance with vaccination were assessed using polytomous logistic regression.
Results |
A total of 2529 patients (75%) received the pneumococcal vaccine and 2812 (84%) received the influenza vaccine. Predictors of noncompliance with the pneumococcal vaccine were perceived lack of recommendation by the general practitioner (odds ratio [OR] = 4.6; 95% confidence interval [CI], 2.6 to 8.3) and fear of local side effects (OR = 2.8; 95% CI, 1.6 to 4.6). Predictors of noncompliance with both vaccinations also included unwillingness to comply with the doctor’s advice (OR = 6.1; 95% CI, 2.4 to 15.4), the belief that vaccinations weaken one’s natural defenses (OR = 2.7; 95% CI, 1.4 to 5.3) or that influenza is not dangerous (OR = 2.9; 95% CI, 1.5 to 5.4), and the fear of becoming sick from pneumococcal vaccination (OR = 2.9; 95% CI, 1.1 to 7.9). People who felt healthy found it difficult to visit the doctor’s office, had private medical insurance, or were younger than 75 years of age also had a greater risk of not being vaccinated.
Conclusion |
Introducing a pneumococcal vaccine to an existing influenza immunization program resulted in high pneumococcal and influenza vaccination rates. A wider diversity of patient characteristics and attitudes was present when neither vaccination was received.
Le texte complet de cet article est disponible en PDF.Plan
The influenza vaccination was paid for by the Dutch government, and a grant from the medical insurance company ANOVA and Pneumokokken Stichting (Foundation for Pneumococcal Infections) covered the general practitioners’ fees and the retail cost of the pneumococcal vaccine. |
Vol 111 - N° 6
P. 474-479 - octobre 2001 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?